Mangoceuticals (MGRX) Net Equity Issued and Repurchased (2023 - 2025)

Mangoceuticals has disclosed Net Equity Issued and Repurchased across 3 years of filings, most recently posting $2.2 million for Q4 2025.

• In Q4 2025, Net Equity Issued and Repurchased rose 191.45% year-over-year to $2.2 million; the TTM figure through Dec 2025 stood at $4.6 million (up 248.22% YoY), while the FY2025 annual figure was $4.6 million, up 248.22% from the prior year.
• Net Equity Issued and Repurchased came in at $2.2 million for Q4 2025 at Mangoceuticals, up from $1.3 million in the prior quarter.
• In the past five years, Net Equity Issued and Repurchased ranged from a high of $5.0 million in Q1 2023 to a low of $180000.0 in Q1 2024.
• Average Net Equity Issued and Repurchased over 3 years is $1.3 million, with a median of $707499.0 recorded in 2024.
• Year-over-year, Net Equity Issued and Repurchased sank 96.4% in 2024 and soared 263.89% in 2025.
• Over 3 years, Net Equity Issued and Repurchased stood at $1.2 million in 2023, then sank by 36.67% to $759998.0 in 2024, then surged by 191.45% to $2.2 million in 2025.
• Per Business Quant data, the three most recent Net Equity Issued and Repurchased figures were $2.2 million in Q4 2025, $1.3 million in Q3 2025, and $430785.0 in Q2 2025.